> top > docs > PMC:1064895 > spans > 20557-21991 > annotations

PMC:1064895 / 20557-21991 JSONTXT

Annnotations TAB JSON ListView MergeView

test3

Id Subject Object Predicate Lexical cue
T15581 1397-1406 Positive_regulation denotes activated
T15580 1383-1393 Gene_expression denotes production
T15579 1377-1382 Protein denotes IL-17
T15578 1282-1286 Protein denotes CD28
T15577 1212-1216 Protein denotes AP-1
T15576 1140-1145 Protein denotes IκB-α
T15575 1125-1136 Protein_catabolism denotes degradation
T15574 1111-1121 Negative_regulation denotes inhibition
T15573 1098-1103 Protein denotes IκB-α
T15572 1051-1056 Protein denotes IL-17
T15571 1027-1034 Binding denotes binding
T15570 1011-1016 Negative_regulation denotes block
T15569 789-793 Protein denotes CD28
T15568 670-675 Protein denotes c-Rel
T15567 643-646 Protein denotes p50
T15566 635-638 Protein denotes p65
T15565 524-529 Protein denotes IL-17
T15564 504-511 Binding denotes binding
T15563 494-503 Positive_regulation denotes increased
T15562 467-471 Protein denotes CD28
T15561 374-379 Protein denotes IL-17
T15560 255-265 Gene_expression denotes expression
T15559 249-254 Protein denotes IL-17
T15558 240-248 Negative_regulation denotes inducing
T15557 213-218 Protein denotes IL-15
T15556 205-208 Protein denotes PHA
T15555 183-187 Protein denotes CD28
T15554 70-75 Protein denotes IL-17
T15553 49-53 Protein denotes AP-1
T15552 28-47 Protein denotes activator protein-1
T15551 1377-1382 Protein denotes IL-17
T15550 1282-1286 Protein denotes CD28
T15549 1212-1216 Protein denotes AP-1
T15548 1140-1145 Protein denotes IκB-α
T15547 1098-1103 Protein denotes IκB-α
T15546 1051-1056 Protein denotes IL-17
T15545 789-793 Protein denotes CD28
T15544 670-675 Protein denotes c-Rel
T15543 643-646 Protein denotes p50
T15542 635-638 Protein denotes p65
T15541 524-529 Protein denotes IL-17
T15540 467-471 Protein denotes CD28
T15539 374-379 Protein denotes IL-17
T15538 249-254 Protein denotes IL-17
T15537 213-218 Protein denotes IL-15
T15536 205-208 Protein denotes PHA
T15535 183-187 Protein denotes CD28
T15534 70-75 Protein denotes IL-17
T15533 49-53 Protein denotes AP-1
T15532 28-47 Protein denotes activator protein-1
R8554 T15553 T15552 equivalentTo AP-1,activator protein-1
R8555 T15556 T15558 causeOf PHA,inducing
R8556 T15559 T15560 themeOf IL-17,expression
R8557 T15560 T15558 themeOf expression,inducing
R8558 T15564 T15563 themeOf binding,increased
R8559 T15571 T15570 themeOf binding,block
R8560 T15575 T15574 themeOf degradation,inhibition
R8561 T15576 T15574 themeOf IκB-α,inhibition
R8562 T15576 T15575 themeOf IκB-α,degradation
R8563 T15579 T15580 themeOf IL-17,production

BioNLP16_Messiy

Id Subject Object Predicate Lexical cue
T16333 1377-1382 Protein denotes IL-17
T16342 1383-1393 Gene_expression denotes production
T16341 1111-1121 Negative_regulation denotes inhibition
T16340 1125-1136 Protein_catabolism denotes degradation
T16339 504-511 Binding denotes binding
T16338 494-503 Positive_regulation denotes increased
T16337 240-248 Positive_regulation denotes inducing
T16336 151-160 Positive_regulation denotes activated
T16335 255-265 Gene_expression denotes expression
T16334 0-10 Positive_regulation denotes Activation
T16332 1282-1286 Protein denotes CD28
T16331 1212-1216 Protein denotes AP-1
T16330 1140-1145 Protein denotes IκB-α
T16329 1098-1103 Protein denotes IκB-α
T16328 1051-1056 Protein denotes IL-17
T16327 789-793 Protein denotes CD28
T16326 670-675 Protein denotes c-Rel
T16325 643-646 Protein denotes p50
T16324 635-638 Protein denotes p65
T16323 467-471 Protein denotes CD28
T16322 524-529 Protein denotes IL-17
T16321 374-379 Protein denotes IL-17
T16320 249-254 Protein denotes IL-17
T16319 213-218 Protein denotes IL-15
T16318 205-208 Protein denotes PHA
T16317 183-187 Protein denotes CD28
T16316 70-75 Protein denotes IL-17
T16315 49-53 Protein denotes AP-1
T16314 28-47 Protein denotes activator protein-1
R8861 T16315 T16334 themeOf AP-1,Activation
R8862 T16318 T16336 themeOf PHA,activated
R8863 T16319 T16336 causeOf IL-15,activated
R8864 T16320 T16335 themeOf IL-17,expression
R8865 T16322 T16339 themeOf IL-17,binding
R8866 T16330 T16340 themeOf IκB-α,degradation
R8867 T16333 T16342 themeOf IL-17,production
R8868 T16335 T16337 themeOf expression,inducing
R8869 T16339 T16338 themeOf binding,increased
R8870 T16340 T16341 themeOf degradation,inhibition

BioNLP16_DUT

Id Subject Object Predicate Lexical cue
T16808 1383-1393 Gene_expression denotes production
T16807 1111-1121 Negative_regulation denotes inhibition
T16806 1125-1136 Protein_catabolism denotes degradation
T16805 1011-1016 Negative_regulation denotes block
T16804 504-511 Binding denotes binding
T16803 240-248 Positive_regulation denotes inducing
T16802 255-265 Gene_expression denotes expression
T16801 0-10 Positive_regulation denotes Activation
T16800 1377-1382 Protein denotes IL-17
T16799 1282-1286 Protein denotes CD28
T16798 1212-1216 Protein denotes AP-1
T16797 1140-1145 Protein denotes IκB-α
T16796 1098-1103 Protein denotes IκB-α
T16795 1051-1056 Protein denotes IL-17
T16794 789-793 Protein denotes CD28
T16793 670-675 Protein denotes c-Rel
T16792 643-646 Protein denotes p50
T16791 635-638 Protein denotes p65
T16790 467-471 Protein denotes CD28
T16789 524-529 Protein denotes IL-17
T16788 374-379 Protein denotes IL-17
T16787 249-254 Protein denotes IL-17
T16786 213-218 Protein denotes IL-15
T16785 205-208 Protein denotes PHA
T16784 183-187 Protein denotes CD28
T16783 70-75 Protein denotes IL-17
T16782 49-53 Protein denotes AP-1
T16781 28-47 Protein denotes activator protein-1
R9191 T16782 T16801 themeOf AP-1,Activation
R9192 T16787 T16802 themeOf IL-17,expression
R9193 T16789 T16804 themeOf IL-17,binding
R9194 T16795 T16805 themeOf IL-17,block
R9195 T16797 T16806 themeOf IκB-α,degradation
R9196 T16800 T16808 themeOf IL-17,production
R9197 T16802 T16803 themeOf expression,inducing
R9198 T16806 T16807 themeOf degradation,inhibition

biosemtest

Id Subject Object Predicate Lexical cue
T15816 1058-1063 UMLS/C1825592 denotes romot
T15815 527-532 UMLS/C1825592 denotes 17 pr
T15814 376-381 UMLS/C1825592 denotes -17.
T15813 250-255 UMLS/C1825592 denotes L-17
T15812 71-76 UMLS/C1825592 denotes L-17
T15811 1349-1353 UMLS/C0024497 denotes llul
T15788 404-420 UMLS/C1518434 denotes clear extracts f
T15787 570-578 UMLS/C0332298 denotes trols (l
T15786 862-866 UMLS/C1517892 denotes bet
T15785 241-249 UMLS/C0205263 denotes nducing
T15784 1283-1287 UMLS/C0332287 denotes D28
T15783 783-787 UMLS/C0332287 denotes ant
T15782 459-463 UMLS/C0332287 denotes us a
T15781 174-178 UMLS/C0332287 denotes lus
T15780 1134-1145 UMLS/C0243125 denotes on of IκB-α
T15779 638-641 UMLS/C1335610 denotes an
T15778 943-950 UMLS/C0243122 denotes g activ
T15777 506-513 UMLS/C0243122 denotes nding o
T15776 692-698 UMLS/C2347086 denotes mal PB
T15775 1010-1016 UMLS/C1521826 denotes block
T15774 1349-1353 UMLS/C0205225 denotes llul
T15773 1120-1130 UMLS/C1628982 denotes n of degra
T15772 496-505 UMLS/C0205217 denotes creased b
T15771 1185-1189 UMLS/C1692345 denotes Fig.
T15770 708-712 UMLS/C1692345 denotes e pa
T15769 602-607 UMLS/C0005507 denotes ay de
T15768 315-320 UMLS/C0005507 denotes ssay
T15767 1190-1194 UMLS/C1704250 denotes 7c).
T15766 692-698 UMLS/C0439166 denotes mal PB
T15765 1419-1423 UMLS/C1321301 denotes tien
T15764 831-835 UMLS/C1321301 denotes (Fi
T15763 699-703 UMLS/C1321301 denotes C th
T15762 429-433 UMLS/C1321301 denotes MC s
T15761 1042-1050 UMLS/C0439167 denotes y in the
T15760 951-959 UMLS/C0439167 denotes ty after
T15759 880-888 UMLS/C0439167 denotes vity and
T15758 638-641 UP/P48018 denotes an
T15757 1228-1235 UMLS/C1704259 denotes not ac
T15756 56-63 UMLS/C1704259 denotes athway
T15755 570-578 UMLS/C0243148 denotes trols (l
T15754 1299-1303 UMLS/C1511726 denotes own)
T15753 914-918 UMLS/C0596608 denotes to d
T15752 322-326 UMLS/C0596608 denotes MSA)
T15751 646-649 UMLS/C1539081 denotes (l
T15750 629-634 UMLS/C0439645 denotes ds in
T15749 1349-1353 UMLS/C1542147 denotes llul
T15748 638-641 UMLS/C1420556 denotes an
T15747 1368-1385 UMLS/C0037080 denotes thway in IL-17 pr
T15746 134-151 UMLS/C0037080 denotes ignaling pathway
T15745 673-678 UMLS/C0035018 denotes el (l
T15744 338-349 UMLS/C0524637 denotes cognition s
T15743 1223-1227 UP/P21525 denotes y wa
T15742 50-54 UP/P21525 denotes P-1)
T15741 638-641 UMLS/C0599933 denotes an
T15740 875-879 UMLS/C1705325 denotes act
T15739 725-733 UMLS/C1441672 denotes erved, b
T15738 570-578 UMLS/C1547100 denotes trols (l
T15737 862-866 UMLS/C0208973 denotes bet
T15736 943-950 UMLS/C1689898 denotes g activ
T15735 506-513 UMLS/C1689898 denotes nding o
T15734 743-749 UMLS/C0449286 denotes ree of
T15733 692-698 UMLS/C1873497 denotes mal PB
T15732 638-641 UP/P21521 denotes an
T15731 1042-1050 UMLS/C0441655 denotes y in the
T15730 951-959 UMLS/C0441655 denotes ty after
T15729 880-888 UMLS/C0441655 denotes vity and
T15728 1120-1130 UMLS/C0021467 denotes n of degra
T15727 1120-1130 UMLS/C0021469 denotes n of degra
T15726 1354-1367 UMLS/C0178719 denotes r signaling p
T15725 120-133 UMLS/C0178719 denotes ntracellular
T15724 1196-1199 UMLS/C0349966 denotes n c
T15723 1074-1077 UMLS/C0349966 denotes ).
T15722 837-840 UMLS/C0349966 denotes 7b
T15721 395-398 UMLS/C0349966 denotes g.
T15720 1223-1227 UP/A8MPH9 denotes y wa
T15719 50-54 UP/A8MPH9 denotes P-1)
T15718 496-505 UMLS/C0442805 denotes creased b
T15717 496-505 UMLS/C0442808 denotes creased b
T15716 1190-1194 UMLS/C0449243 denotes 7c).
T15715 914-918 UMLS/C0949632 denotes to d
T15714 322-326 UMLS/C0949632 denotes MSA)
T15713 546-556 UMLS/C1707455 denotes parison wi
T15712 1190-1194 UMLS/C0040223 denotes 7c).
T15711 570-578 UMLS/C1550141 denotes trols (l
T15710 629-634 UMLS/C0185014 denotes ds in
T15709 621-628 UMLS/C0333051 denotes fted ba
T15708 1010-1016 UMLS/C1254351 denotes block
T15707 1223-1227 UMLS/C0087140 denotes y wa
T15706 50-54 UMLS/C0087140 denotes P-1)
T15705 743-749 UMLS/C0542560 denotes ree of
T15704 350-355 UMLS/C1546778 denotes tes i
T15703 214-219 UMLS/C1149222 denotes L-15,
T15702 77-92 UMLS/C0033413 denotes romoter region
T15701 206-209 UMLS/C0030779 denotes HA
T15700 850-857 UMLS/C1446409 denotes irm the
T15699 743-749 UMLS/C0441889 denotes ree of
T15698 638-641 UP/P47191 denotes an
T15697 96-107 UMLS/C1292732 denotes nvestigate
T15696 214-219 UMLS/C0254610 denotes L-15,
T15695 256-266 UMLS/C0185117 denotes xpression,
T15694 602-607 UMLS/C1510438 denotes ay de
T15693 315-320 UMLS/C1510438 denotes ssay
T15692 713-720 UMLS/C0449774 denotes tern wa
T15691 646-649 UP/P83939 denotes (l
T15690 1409-1418 UMLS/C1879547 denotes MC from p
T15689 1244-1253 UMLS/C1879547 denotes y stimula
T15688 760-770 UMLS/C1879547 denotes vation by
T15687 152-161 UMLS/C1879547 denotes ctivated
T15686 0-10 UMLS/C1879547 denotes Activation
T15685 214-219 UMLS/C1334105 denotes L-15,
T15684 350-355 UMLS/C2347790 denotes tes i
T15683 1223-1227 UMLS/C0162508 denotes y wa
T15682 50-54 UMLS/C0162508 denotes P-1)
T15681 646-649 UMLS/C1417708 denotes (l
T15680 960-975 UMLS/C0001758 denotes treatment with
T15679 225-236 UMLS/C1273518 denotes esponsible
T15678 1223-1227 UMLS/C1333571 denotes y wa
T15677 50-54 UMLS/C1333571 denotes P-1)
T15676 1257-1268 UMLS/C1948023 denotes with anti-
T15675 434-444 UMLS/C1948023 denotes imulated w
T15674 1084-1100 UMLS/C0005863 denotes blotting for Iκ
T15673 570-578 UMLS/C0009932 denotes trols (l
T15672 875-879 UP/P42336 denotes act
T15671 904-913 UMLS/C0884358 denotes rmed EMSA
T15670 271-280 UMLS/C0884358 denotes erformed
T15669 1084-1100 UMLS/C0949466 denotes blotting for Iκ
T15668 1134-1145 UMLS/C0699900 denotes on of IκB-α
T15667 1160-1168 UMLS/C0251991 denotes d PDTC a
T15666 986-994 UMLS/C0251991 denotes 02 and P
T15665 1058-1063 UMLS/C1522571 denotes romot
T15664 527-532 UMLS/C1522571 denotes 17 pr
T15663 376-381 UMLS/C1522571 denotes -17.
T15662 250-255 UMLS/C1522571 denotes L-17
T15661 71-76 UMLS/C1522571 denotes L-17
T15660 1257-1268 UMLS/C1292856 denotes with anti-
T15659 1173-1177 UMLS/C0084183 denotes sam
T15658 999-1003 UMLS/C0084183 denotes Both
T15657 1354-1367 UMLS/C0175996 denotes r signaling p
T15656 120-133 UMLS/C0175996 denotes ntracellular
T15655 1010-1016 UMLS/C0450442 denotes block
T15654 1058-1063 UMLS/C0384648 denotes romot
T15653 527-532 UMLS/C0384648 denotes 17 pr
T15652 376-381 UMLS/C0384648 denotes -17.
T15651 250-255 UMLS/C0384648 denotes L-17
T15650 71-76 UMLS/C0384648 denotes L-17
T15649 1042-1050 UMLS/C1561536 denotes y in the
T15648 951-959 UMLS/C1561536 denotes ty after
T15647 880-888 UMLS/C1561536 denotes vity and
T15646 256-266 UMLS/C0017262 denotes xpression,
T15645 875-879 UMLS/C1368105 denotes act
T15644 904-913 UMLS/C1550369 denotes rmed EMSA
T15643 271-280 UMLS/C1550369 denotes erformed
T15642 922-931 UMLS/C0521095 denotes mine the
T15641 1017-1022 UMLS/C0332206 denotes NF-κB
T15640 850-857 UMLS/C0521093 denotes irm the
T15639 1017-1022 UMLS/C1706084 denotes NF-κB
T15638 1190-1194 UMLS/C1548318 denotes 7c).
T15637 350-355 UMLS/C0205145 denotes tes i
T15636 602-607 UMLS/C0243073 denotes ay de
T15635 315-320 UMLS/C0243073 denotes ssay
T15634 850-857 UMLS/C1456348 denotes irm the
T15633 1368-1385 UMLS/C0086982 denotes thway in IL-17 pr
T15632 134-151 UMLS/C0086982 denotes ignaling pathway
T15631 943-950 UMLS/C1167622 denotes g activ
T15630 506-513 UMLS/C1167622 denotes nding o
T15629 1017-1022 UMLS/C1533157 denotes NF-κB
T15628 1058-1063 UMLS/C1623218 denotes romot
T15627 527-532 UMLS/C1623218 denotes 17 pr
T15626 376-381 UMLS/C1623218 denotes -17.
T15625 250-255 UMLS/C1623218 denotes L-17
T15624 71-76 UMLS/C1623218 denotes L-17
T15623 646-649 UP/Q05894 denotes (l
T15622 743-749 UMLS/C1561545 denotes ree of
T15621 646-649 UP/P23061 denotes (l
T15620 400-402 UMLS/C1553639 denotes ,
T15619 1190-1194 UMLS/C1547403 denotes 7c).
T15618 1190-1194 UMLS/C1632851 denotes 7c).
T15617 692-698 UMLS/C1704701 denotes mal PB
T15616 190-204 UMLS/C0009630 denotes oncanavalin A,
T15615 735-738 UMLS/C0005341 denotes th
T15614 875-879 UMLS/C0285761 denotes act
T15613 638-641 UP/P41823 denotes an
T15612 919-921 UMLS/C0319022 denotes te
T15611 847-849 UMLS/C0319022 denotes on
T15610 524-526 UMLS/C0319022 denotes IL
T15609 93-95 UMLS/C0319022 denotes o
T15608 1190-1194 UMLS/C0392761 denotes 7c).
T15607 1017-1022 UMLS/C0028778 denotes NF-κB
T15606 692-698 UMLS/C1550457 denotes mal PB
T15605 1017-1022 UMLS/C0233660 denotes NF-κB
T15604 1064-1072 UMLS/C0086860 denotes r (Fig.
T15603 533-542 UMLS/C0086860 denotes moters in
T15602 363-372 UMLS/C0086860 denotes omoters o
T15601 1223-1227 UMLS/C0812312 denotes y wa
T15600 50-54 UMLS/C0812312 denotes P-1)
T15599 850-857 UMLS/C0750484 denotes irm the
T15598 350-355 UMLS/C1515974 denotes tes i
T15597 943-950 UMLS/C1145667 denotes g activ
T15596 506-513 UMLS/C1145667 denotes nding o
T15595 1185-1189 UMLS/C0445247 denotes Fig.
T15594 708-712 UMLS/C0445247 denotes e pa
T15593 692-698 UMLS/C1551394 denotes mal PB
T15592 943-950 UMLS/C2349209 denotes g activ
T15591 506-513 UMLS/C2349209 denotes nding o
T15590 807-814 UMLS/C0522510 denotes nse tha
T15589 1223-1227 UMLS/C0085828 denotes y wa
T15588 50-54 UMLS/C0085828 denotes P-1)
T15587 29-48 UMLS/C0085828 denotes ctivator protein-1
T15586 646-649 UMLS/C1705525 denotes (l
T15585 1209-1217 UMLS/C1979874 denotes he AP-1
T15584 570-578 UMLS/C1882979 denotes trols (l
T15583 1030-1041 UMLS/C1148673 denotes ding activi
T15582 862-866 UMLS/C1704666 denotes bet
T15810 1389-1405 UMLS/C1819444 denotes tion by activate
T15809 646-649 UP/Q28618 denotes (l
T15808 570-578 UMLS/C2587213 denotes trols (l
T15807 1010-1016 UMLS/C1551364 denotes block
T15806 621-628 UMLS/C2347509 denotes fted ba
T15805 638-641 UP/P21707 denotes an
T15804 629-634 UMLS/C0175723 denotes ds in
T15803 692-698 UMLS/C0205307 denotes mal PB
T15802 638-641 UP/P46096 denotes an
T15801 638-641 UP/P21579 denotes an
T15800 743-749 UMLS/C2348088 denotes ree of
T15799 1228-1235 UMLS/C1705987 denotes not ac
T15798 56-63 UMLS/C1705987 denotes athway
T15797 875-879 UMLS/C1150481 denotes act
T15796 1304-1307 UMLS/C1518422 denotes de
T15795 1240-1243 UMLS/C1518422 denotes ed
T15794 666-669 UMLS/C1518422 denotes in
T15793 680-684 UMLS/C1708639 denotes e 5)
T15792 651-656 UMLS/C1708639 denotes es 3
T15791 580-584 UMLS/C1708639 denotes e 1)
T15790 475-479 UMLS/C1708639 denotes ne 2
T15789 206-209 UMLS/C0031858 denotes HA

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T16026 740-746 NN denotes degree
T16025 736-739 DT denotes the
T16024 732-735 CC denotes but
T16023 730-731 -COMMA- denotes ,
T16022 722-730 VB denotes observed
T16021 718-721 VB denotes was
T16020 710-717 NN denotes pattern
T16019 705-709 JJ denotes same
T16018 701-704 DT denotes the
T16017 696-700 NN denotes PBMC
T16016 689-695 JJ denotes normal
T16015 686-688 IN denotes In
T16014 683-684 -RRB- denotes )
T16013 682-683 CD denotes 5
T16012 677-681 NN denotes lane
T16011 676-677 -LRB- denotes (
T16010 670-675 NN denotes c-Rel
T16009 667-669 IN denotes in
T16008 663-666 RB denotes not
T16007 661-662 -RRB- denotes )
T16006 660-661 CD denotes 4
T16005 656-659 CC denotes and
T16004 654-655 CD denotes 3
T16003 648-653 NN denotes lanes
T16002 647-648 -LRB- denotes (
T16001 643-646 NN denotes p50
T16000 639-642 CC denotes and
T15999 635-638 NN denotes p65
T15998 632-634 IN denotes in
T15997 626-631 NN denotes bands
T15996 618-625 VB denotes shifted
T15995 605-617 VB denotes demonstrated
T15994 599-604 NN denotes assay
T15993 588-598 NN denotes supershift
T15992 586-587 DT denotes A
T15991 583-584 -RRB- denotes )
T15990 582-583 CD denotes 1
T15989 577-581 NN denotes lane
T15988 576-577 -LRB- denotes (
T15987 567-575 NN denotes controls
T15986 564-566 IN denotes of
T15985 559-563 DT denotes that
T15984 554-558 IN denotes with
T15983 543-553 NN denotes comparison
T15982 540-542 IN denotes in
T15981 530-539 NN denotes promoters
T15980 524-529 NN denotes IL-17
T15979 521-523 TO denotes to
T15978 515-520 NN denotes NF-κB
T15977 512-514 IN denotes of
T15976 504-511 NN denotes binding
T15975 494-503 VB denotes increased
T15974 481-493 VB denotes demonstrated
T15973 479-480 -RRB- denotes )
T15972 478-479 CD denotes 2
T15971 473-477 NN denotes lane
T15970 472-473 -LRB- denotes (
T15969 462-471 NN denotes anti-CD28
T15968 457-461 CC denotes plus
T15967 448-456 JJ denotes anti-CD3
T15966 443-447 IN denotes with
T15965 432-442 VB denotes stimulated
T15964 427-431 NN denotes PBMC
T15963 424-426 NN denotes RA
T15962 419-423 IN denotes from
T15961 410-418 NN denotes extracts
T15960 402-409 JJ denotes nuclear
T15959 400-401 -COMMA- denotes ,
T15958 398-400 NNP denotes 7a
T15957 393-397 NNP denotes Fig.
T15956 390-392 IN denotes in
T15955 384-389 VB denotes shown
T15954 381-383 IN denotes As
T15953 374-379 NN denotes IL-17
T15952 371-373 IN denotes of
T15951 361-370 NN denotes promoters
T15950 357-360 DT denotes the
T15949 354-356 IN denotes in
T15948 348-353 NN denotes sites
T15947 336-347 NN denotes recognition
T15946 330-335 NN denotes NF-κB
T15945 327-329 IN denotes of
T15944 325-326 -RRB- denotes )
T15943 321-325 NN denotes EMSA
T15942 320-321 -LRB- denotes (
T15941 314-319 NN denotes assay
T15940 299-313 NN denotes mobility-shift
T15939 283-298 JJ denotes electrophoretic
T15938 280-282 DT denotes an
T15937 270-279 VB denotes performed
T15936 267-269 PRP denotes we
T15935 265-266 -COMMA- denotes ,
T15934 255-265 NN denotes expression
T15933 249-254 NN denotes IL-17
T15932 240-248 VB denotes inducing
T15931 236-239 IN denotes for
T15930 224-235 JJ denotes responsible
T15929 220-223 CC denotes and
T15928 218-219 -COMMA- denotes ,
T15927 213-218 NN denotes IL-15
T15926 209-212 CC denotes and
T15925 205-208 NN denotes PHA
T15924 203-204 -COMMA- denotes ,
T15923 202-203 NN denotes A
T15922 189-201 NN denotes concanavalin
T15921 187-188 -COMMA- denotes ,
T15920 178-187 NN denotes anti-CD28
T15919 173-177 CC denotes plus
T15918 164-172 JJ denotes anti-CD3
T15917 161-163 IN denotes by
T15916 151-160 VB denotes activated
T15915 143-150 NN denotes pathway
T15914 133-142 NN denotes signaling
T15913 119-132 JJ denotes intracellular
T15912 115-118 DT denotes the
T15911 107-114 RB denotes further
T15910 95-106 VB denotes investigate
T15909 92-94 TO denotes To
T15908 85-91 NN denotes region
T15907 76-84 NN denotes promoter
T15906 70-75 NN denotes IL-17
T15905 66-69 DT denotes the
T15904 63-65 IN denotes in
T15903 55-62 NN denotes pathway
T15902 53-54 -RRB- denotes )
T15901 49-53 NN denotes AP-1
T15900 48-49 -LRB- denotes (
T15899 38-47 NN denotes protein-1
T15898 28-37 NN denotes activator
T15897 24-27 CC denotes and
T15896 18-23 NN denotes NF-κB
T15895 14-17 DT denotes the
T15894 11-13 IN denotes of
T15893 0-10 NN denotes Activation
T16086 1077-1084 NN denotes Western
T16085 1074-1075 -RRB- denotes )
T16147 1431-1433 NN denotes RA
T16146 1426-1430 IN denotes with
T16145 1417-1425 NN denotes patients
T16144 1412-1416 IN denotes from
T16143 1407-1411 NN denotes PBMC
T16142 1397-1406 VB denotes activated
T16141 1394-1396 IN denotes by
T16140 1383-1393 NN denotes production
T16139 1377-1382 NN denotes IL-17
T16138 1374-1376 IN denotes in
T16137 1366-1373 NN denotes pathway
T16136 1356-1365 NN denotes signaling
T16135 1342-1355 JJ denotes intracellular
T16134 1337-1341 JJ denotes main
T16133 1333-1336 DT denotes the
T16132 1330-1332 VB denotes is
T16131 1324-1329 NN denotes NF-κB
T16130 1319-1323 IN denotes that
T16129 1305-1318 VB denotes demonstrating
T16128 1303-1304 -COMMA- denotes ,
T16127 1302-1303 -RRB- denotes )
T16126 1297-1302 VB denotes shown
T16125 1293-1296 RB denotes not
T16124 1288-1292 NN denotes data
T16123 1287-1288 -LRB- denotes (
T16122 1277-1286 JJ denotes anti-CD28
T16121 1272-1276 CC denotes plus
T16120 1263-1271 JJ denotes anti-CD3
T16119 1258-1262 IN denotes with
T16118 1246-1257 NN denotes stimulation
T16117 1243-1245 IN denotes by
T16116 1233-1242 VB denotes activated
T16115 1229-1232 RB denotes not
T16114 1225-1228 VB denotes was
T16113 1217-1224 NN denotes pathway
T16112 1212-1216 NN denotes AP-1
T16111 1208-1211 DT denotes the
T16110 1206-1207 -COMMA- denotes ,
T16109 1198-1206 NN denotes contrast
T16108 1195-1197 IN denotes In
T16107 1192-1193 -RRB- denotes )
T16106 1190-1192 NN denotes 7c
T16105 1185-1189 NN denotes Fig.
T16104 1184-1185 -LRB- denotes (
T16103 1179-1183 NN denotes time
T16102 1174-1178 JJ denotes same
T16101 1170-1173 DT denotes the
T16100 1167-1169 IN denotes at
T16099 1162-1166 NN denotes PDTC
T16098 1158-1161 CC denotes and
T16097 1149-1157 NN denotes LY294002
T16096 1146-1148 IN denotes by
T16095 1140-1145 NN denotes IκB-α
T16094 1137-1139 IN denotes of
T16093 1125-1136 NN denotes degradation
T16092 1122-1124 IN denotes of
T16091 1111-1121 NN denotes inhibition
T16090 1104-1110 VB denotes showed
T16089 1098-1103 NN denotes IκB-α
T16088 1094-1097 IN denotes for
T16087 1085-1093 NN denotes blotting
T16084 1072-1074 NN denotes 7c
T16083 1067-1071 NN denotes Fig.
T16082 1066-1067 -LRB- denotes (
T16081 1057-1065 NN denotes promoter
T16080 1051-1056 NN denotes IL-17
T16079 1047-1050 DT denotes the
T16078 1044-1046 IN denotes in
T16077 1035-1043 NN denotes activity
T16076 1023-1034 JJ denotes DNA-binding
T16075 1017-1022 NN denotes NF-κB
T16074 1011-1016 VB denotes block
T16073 1004-1010 NN denotes agents
T16072 999-1003 DT denotes Both
T16071 993-997 NN denotes PDTC
T16070 989-992 CC denotes and
T16069 980-988 NN denotes LY294002
T16068 975-979 CC denotes both
T16067 970-974 IN denotes with
T16066 960-969 NN denotes treatment
T16065 954-959 IN denotes after
T16064 945-953 NN denotes activity
T16063 937-944 NN denotes binding
T16062 931-936 NN denotes NF-κB
T16061 927-930 DT denotes the
T16060 917-926 VB denotes determine
T16059 914-916 TO denotes to
T16058 909-913 NN denotes EMSA
T16057 899-908 VB denotes performed
T16056 896-898 PRP denotes we
T16055 894-895 -COMMA- denotes ,
T16054 889-894 NN denotes NF-κB
T16053 885-888 CC denotes and
T16052 876-884 NN denotes activity
T16051 871-875 NN denotes PI3K
T16050 863-870 IN denotes between
T16049 858-862 NN denotes link
T16048 854-857 DT denotes the
T16047 846-853 VB denotes confirm
T16046 843-845 TO denotes To
T16045 840-841 -RRB- denotes )
T16044 838-840 NN denotes 7b
T16043 833-837 NN denotes Fig.
T16042 832-833 -LRB- denotes (
T16041 827-831 NN denotes PBMC
T16040 824-826 NN denotes RA
T16039 821-823 IN denotes in
T16038 816-820 DT denotes that
T16037 811-815 IN denotes than
T16036 803-810 JJ denotes intense
T16035 798-802 RB denotes less
T16034 794-797 VB denotes was
T16033 784-793 NN denotes anti-CD28
T16032 779-783 CC denotes plus
T16031 770-778 NN denotes anti-CD3
T16030 767-769 IN denotes by
T16029 756-766 NN denotes activation
T16028 750-755 NN denotes NF-κB
T16027 747-749 IN denotes of
R8583 T15893 T15894 arg1Of Activation,of
R8584 T15893 T15904 arg1Of Activation,in
R8585 T15896 T15897 arg1Of NF-κB,and
R8586 T15899 T15897 arg2Of protein-1,and
R8587 T15899 T15898 arg1Of protein-1,activator
R8588 T15899 T15900 arg1Of protein-1,(
R8589 T15901 T15900 arg2Of AP-1,(
R8590 T15902 T15900 arg3Of ),(
R8591 T15903 T15894 arg2Of pathway,of
R8592 T15903 T15895 arg1Of pathway,the
R8593 T15903 T15896 arg1Of pathway,NF-κB
R8594 T15903 T15899 arg1Of pathway,protein-1
R8595 T15908 T15904 arg2Of region,in
R8596 T15908 T15905 arg1Of region,the
R8597 T15908 T15906 arg1Of region,IL-17
R8598 T15908 T15907 arg1Of region,promoter
R8599 T15910 T15909 arg1Of investigate,To
R8600 T15910 T15911 arg1Of investigate,further
R8601 T15915 T15910 arg2Of pathway,investigate
R8602 T15915 T15912 arg1Of pathway,the
R8603 T15915 T15913 arg1Of pathway,intracellular
R8604 T15915 T15914 arg1Of pathway,signaling
R8605 T15915 T15916 arg2Of pathway,activated
R8606 T15915 T15930 arg1Of pathway,responsible
R8607 T15916 T15929 arg1Of activated,and
R8608 T15918 T15919 arg1Of anti-CD3,plus
R8609 T15919 T15921 arg1Of plus,","
R8610 T15920 T15919 arg2Of anti-CD28,plus
R8611 T15921 T15924 arg1Of ",",","
R8612 T15923 T15921 arg2Of A,","
R8613 T15923 T15922 arg1Of A,concanavalin
R8614 T15924 T15926 arg1Of ",",and
R8615 T15925 T15924 arg2Of PHA,","
R8616 T15926 T15916 arg1Of and,activated
R8617 T15926 T15917 arg2Of and,by
R8618 T15927 T15926 arg2Of IL-15,and
R8619 T15929 T15928 arg1Of and,","
R8620 T15930 T15929 arg2Of responsible,and
R8621 T15930 T15931 arg1Of responsible,for
R8622 T15932 T15931 arg2Of inducing,for
R8623 T15934 T15932 arg2Of expression,inducing
R8624 T15934 T15933 arg1Of expression,IL-17
R8625 T15936 T15937 arg1Of we,performed
R8626 T15937 T15909 modOf performed,To
R8627 T15937 T15935 arg1Of performed,","
R8628 T15941 T15937 arg2Of assay,performed
R8629 T15941 T15938 arg1Of assay,an
R8630 T15941 T15939 arg1Of assay,electrophoretic
R8631 T15941 T15940 arg1Of assay,mobility-shift
R8632 T15941 T15942 arg1Of assay,(
R8633 T15941 T15945 arg1Of assay,of
R8634 T15943 T15942 arg2Of EMSA,(
R8635 T15944 T15942 arg3Of ),(
R8636 T15948 T15945 arg2Of sites,of
R8637 T15948 T15946 arg1Of sites,NF-κB
R8638 T15948 T15947 arg1Of sites,recognition
R8639 T15948 T15949 arg1Of sites,in
R8640 T15951 T15949 arg2Of promoters,in
R8641 T15951 T15950 arg1Of promoters,the
R8642 T15951 T15952 arg1Of promoters,of
R8643 T15953 T15952 arg2Of IL-17,of
R8644 T15955 T15954 arg2Of shown,As
R8645 T15955 T15956 arg1Of shown,in
R8646 T15958 T15956 arg2Of 7a,in
R8647 T15958 T15957 arg1Of 7a,Fig.
R8648 T15961 T15960 arg1Of extracts,nuclear
R8649 T15961 T15962 arg1Of extracts,from
R8650 T15961 T15974 arg1Of extracts,demonstrated
R8651 T15964 T15962 arg2Of PBMC,from
R8652 T15964 T15963 arg1Of PBMC,RA
R8653 T15964 T15965 arg2Of PBMC,stimulated
R8654 T15965 T15966 arg1Of stimulated,with
R8655 T15967 T15968 arg1Of anti-CD3,plus
R8656 T15968 T15966 arg2Of plus,with
R8657 T15968 T15970 arg1Of plus,(
R8658 T15969 T15968 arg2Of anti-CD28,plus
R8659 T15971 T15970 arg2Of lane,(
R8660 T15971 T15972 arg1Of lane,2
R8661 T15973 T15970 arg3Of ),(
R8662 T15974 T15954 arg1Of demonstrated,As
R8663 T15974 T15959 arg1Of demonstrated,","
R8664 T15974 T15982 arg1Of demonstrated,in
R8665 T15976 T15974 arg2Of binding,demonstrated
R8666 T15976 T15975 arg2Of binding,increased
R8667 T15976 T15977 arg1Of binding,of
R8668 T15976 T15979 arg1Of binding,to
R8669 T15978 T15977 arg2Of NF-κB,of
R8670 T15981 T15979 arg2Of promoters,to
R8671 T15981 T15980 arg1Of promoters,IL-17
R8672 T15983 T15982 arg2Of comparison,in
R8673 T15983 T15984 arg1Of comparison,with
R8674 T15985 T15984 arg2Of that,with
R8675 T15985 T15986 arg1Of that,of
R8676 T15987 T15986 arg2Of controls,of
R8677 T15987 T15988 arg1Of controls,(
R8678 T15989 T15988 arg2Of lane,(
R8679 T15989 T15990 arg1Of lane,1
R8680 T15991 T15988 arg3Of ),(
R8681 T15994 T15992 arg1Of assay,A
R8682 T15994 T15993 arg1Of assay,supershift
R8683 T15994 T15995 arg1Of assay,demonstrated
R8684 T15995 T16009 arg1Of demonstrated,in
R8685 T15997 T15995 arg2Of bands,demonstrated
R8686 T15997 T15996 arg2Of bands,shifted
R8687 T15997 T15998 arg1Of bands,in
R8688 T15999 T16000 arg1Of p65,and
R8689 T16000 T15998 arg2Of and,in
R8690 T16000 T16002 arg1Of and,(
R8691 T16001 T16000 arg2Of p50,and
R8692 T16004 T16005 arg1Of 3,and
R8693 T16005 T16002 arg2Of and,(
R8694 T16005 T16003 arg1Of and,lanes
R8695 T16006 T16005 arg2Of 4,and
R8696 T16007 T16002 arg3Of ),(
R8697 T16009 T16008 arg1Of in,not
R8698 T16010 T16009 arg2Of c-Rel,in
R8699 T16010 T16011 arg1Of c-Rel,(
R8700 T16012 T16011 arg2Of lane,(
R8701 T16012 T16013 arg1Of lane,5
R8702 T16014 T16011 arg3Of ),(
R8703 T16017 T16015 arg2Of PBMC,In
R8704 T16017 T16016 arg1Of PBMC,normal
R8705 T16020 T16018 arg1Of pattern,the
R8706 T16020 T16019 arg1Of pattern,same
R8707 T16020 T16021 arg1Of pattern,was
R8708 T16020 T16022 arg2Of pattern,observed
R8709 T16022 T16015 arg1Of observed,In
R8710 T16022 T16021 arg2Of observed,was
R8711 T16022 T16024 arg1Of observed,but
R8712 T16024 T16023 arg1Of but,","
R8713 T16026 T16025 arg1Of degree,the
R8714 T16026 T16027 arg1Of degree,of
R8715 T16026 T16030 arg1Of degree,by
R8716 T16026 T16034 arg1Of degree,was
R8717 T16026 T16036 arg1Of degree,intense
R8718 T16029 T16027 arg2Of activation,of
R8719 T16029 T16028 arg1Of activation,NF-κB
R8720 T16031 T16032 arg1Of anti-CD3,plus
R8721 T16032 T16030 arg2Of plus,by
R8722 T16033 T16032 arg2Of anti-CD28,plus
R8723 T16034 T16024 arg2Of was,but
R8724 T16036 T16034 arg2Of intense,was
R8725 T16036 T16035 arg1Of intense,less
R8726 T16036 T16037 arg1Of intense,than
R8727 T16038 T16037 arg2Of that,than
R8728 T16038 T16039 arg1Of that,in
R8729 T16041 T16039 arg2Of PBMC,in
R8730 T16041 T16040 arg1Of PBMC,RA
R8731 T16041 T16042 arg1Of PBMC,(
R8732 T16044 T16042 arg2Of 7b,(
R8733 T16044 T16043 arg1Of 7b,Fig.
R8734 T16045 T16042 arg3Of ),(
R8735 T16047 T16046 arg1Of confirm,To
R8736 T16049 T16047 arg2Of link,confirm
R8737 T16049 T16048 arg1Of link,the
R8738 T16049 T16050 arg1Of link,between
R8739 T16052 T16051 arg1Of activity,PI3K
R8740 T16052 T16053 arg1Of activity,and
R8741 T16053 T16050 arg2Of and,between
R8742 T16054 T16053 arg2Of NF-κB,and
R8743 T16056 T16047 arg1Of we,confirm
R8744 T16056 T16057 arg1Of we,performed
R8745 T16057 T16046 modOf performed,To
R8746 T16057 T16055 arg1Of performed,","
R8747 T16058 T16057 arg2Of EMSA,performed
R8748 T16058 T16059 modOf EMSA,to
R8749 T16060 T16059 arg1Of determine,to
R8750 T16060 T16065 arg1Of determine,after
R8751 T16064 T16060 arg2Of activity,determine
R8752 T16064 T16061 arg1Of activity,the
R8753 T16064 T16062 arg1Of activity,NF-κB
R8754 T16064 T16063 arg1Of activity,binding
R8755 T16066 T16065 arg2Of treatment,after
R8756 T16066 T16067 arg1Of treatment,with
R8757 T16069 T16070 arg1Of LY294002,and
R8758 T16070 T16067 arg2Of and,with
R8759 T16070 T16068 arg1Of and,both
R8760 T16071 T16070 arg2Of PDTC,and
R8761 T16073 T16072 arg1Of agents,Both
R8762 T16073 T16074 arg1Of agents,block
R8763 T16077 T16074 arg2Of activity,block
R8764 T16077 T16075 arg1Of activity,NF-κB
R8765 T16077 T16076 arg1Of activity,DNA-binding
R8766 T16077 T16078 arg1Of activity,in
R8767 T16081 T16078 arg2Of promoter,in
R8768 T16081 T16079 arg1Of promoter,the
R8769 T16081 T16080 arg1Of promoter,IL-17
R8770 T16081 T16082 arg1Of promoter,(
R8771 T16084 T16082 arg2Of 7c,(
R8772 T16084 T16083 arg1Of 7c,Fig.
R8773 T16085 T16082 arg3Of ),(
R8774 T16087 T16086 arg1Of blotting,Western
R8775 T16087 T16088 arg1Of blotting,for
R8776 T16087 T16090 arg1Of blotting,showed
R8777 T16089 T16088 arg2Of IκB-α,for
R8778 T16091 T16090 arg2Of inhibition,showed
R8779 T16091 T16092 arg1Of inhibition,of
R8780 T16093 T16092 arg2Of degradation,of
R8781 T16093 T16094 arg1Of degradation,of
R8782 T16093 T16096 arg1Of degradation,by
R8783 T16093 T16100 arg1Of degradation,at
R8784 T16095 T16094 arg2Of IκB-α,of
R8785 T16097 T16098 arg1Of LY294002,and
R8786 T16098 T16096 arg2Of and,by
R8787 T16099 T16098 arg2Of PDTC,and
R8788 T16103 T16100 arg2Of time,at
R8789 T16103 T16101 arg1Of time,the
R8790 T16103 T16102 arg1Of time,same
R8791 T16103 T16104 arg1Of time,(
R8792 T16106 T16104 arg2Of 7c,(
R8793 T16106 T16105 arg1Of 7c,Fig.
R8794 T16107 T16104 arg3Of ),(
R8795 T16109 T16108 arg2Of contrast,In
R8796 T16113 T16111 arg1Of pathway,the
R8797 T16113 T16112 arg1Of pathway,AP-1
R8798 T16113 T16114 arg1Of pathway,was
R8799 T16113 T16116 arg2Of pathway,activated
R8800 T16116 T16108 arg1Of activated,In
R8801 T16116 T16110 arg1Of activated,","
R8802 T16116 T16114 arg2Of activated,was
R8803 T16116 T16115 arg1Of activated,not
R8804 T16116 T16128 arg1Of activated,","
R8805 T16116 T16129 modOf activated,demonstrating
R8806 T16118 T16116 arg1Of stimulation,activated
R8807 T16118 T16117 arg2Of stimulation,by
R8808 T16118 T16119 arg1Of stimulation,with
R8809 T16120 T16121 arg1Of anti-CD3,plus
R8810 T16122 T16121 arg2Of anti-CD28,plus
R8811 T16124 T16119 arg2Of data,with
R8812 T16124 T16120 arg1Of data,anti-CD3
R8813 T16124 T16122 arg1Of data,anti-CD28
R8814 T16124 T16123 arg2Of data,(
R8815 T16124 T16126 arg2Of data,shown
R8816 T16126 T16125 arg1Of shown,not
R8817 T16127 T16123 arg3Of ),(
R8818 T16131 T16132 arg1Of NF-κB,is
R8819 T16132 T16129 arg2Of is,demonstrating
R8820 T16132 T16130 arg1Of is,that
R8821 T16137 T16132 arg2Of pathway,is
R8822 T16137 T16133 arg1Of pathway,the
R8823 T16137 T16134 arg1Of pathway,main
R8824 T16137 T16135 arg1Of pathway,intracellular
R8825 T16137 T16136 arg1Of pathway,signaling
R8826 T16137 T16138 arg1Of pathway,in
R8827 T16137 T16141 arg1Of pathway,by
R8828 T16140 T16138 arg2Of production,in
R8829 T16140 T16139 arg1Of production,IL-17
R8830 T16143 T16141 arg2Of PBMC,by
R8831 T16143 T16142 arg2Of PBMC,activated
R8832 T16143 T16144 arg1Of PBMC,from
R8833 T16145 T16144 arg2Of patients,from
R8834 T16145 T16146 arg1Of patients,with
R8835 T16147 T16146 arg2Of RA,with

bionlp-st-ge-2016-test-proteins

Id Subject Object Predicate Lexical cue
T16167 1377-1382 Protein denotes IL-17
T16166 1282-1286 Protein denotes CD28
T16165 1212-1216 Protein denotes AP-1
T16164 1140-1145 Protein denotes IκB-α
T16163 1098-1103 Protein denotes IκB-α
T16162 1051-1056 Protein denotes IL-17
T16161 789-793 Protein denotes CD28
T16160 670-675 Protein denotes c-Rel
T16159 643-646 Protein denotes p50
T16158 635-638 Protein denotes p65
T16157 524-529 Protein denotes IL-17
T16156 467-471 Protein denotes CD28
T16155 374-379 Protein denotes IL-17
T16154 249-254 Protein denotes IL-17
T16153 213-218 Protein denotes IL-15
T16152 205-208 Protein denotes PHA
T16151 183-187 Protein denotes CD28
T16150 70-75 Protein denotes IL-17
T16149 49-53 Protein denotes AP-1
T16148 28-47 Protein denotes activator protein-1

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T16313 670-675 http://www.uniprot.org/uniprot/Q04864 denotes c-Rel
T16312 643-646 http://www.uniprot.org/uniprot/P19838 denotes p50
T16311 635-638 http://www.uniprot.org/uniprot/P21579 denotes p65
T16310 635-638 http://www.uniprot.org/uniprot/Q04206 denotes p65
T16309 213-218 http://www.uniprot.org/uniprot/P40933 denotes IL-15
T16308 1282-1286 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16307 789-793 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16306 467-471 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16305 183-187 http://www.uniprot.org/uniprot/P10747 denotes CD28
T16304 1268-1271 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16303 775-778 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16302 453-456 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16301 169-172 http://www.uniprot.org/uniprot/P09693 denotes CD3
T16300 1268-1271 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16299 775-778 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16298 453-456 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16297 169-172 http://www.uniprot.org/uniprot/P07766 denotes CD3
T16296 1268-1271 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16295 775-778 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16294 453-456 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16293 169-172 http://www.uniprot.org/uniprot/P04234 denotes CD3
T16292 1268-1271 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16291 775-778 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16290 453-456 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16289 169-172 http://www.uniprot.org/uniprot/P20963 denotes CD3
T16288 1377-1382 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16287 1051-1056 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16286 524-529 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16285 374-379 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16284 249-254 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16283 70-75 http://www.uniprot.org/uniprot/Q16552 denotes IL-17
T16282 1212-1216 http://www.uniprot.org/uniprot/P05412 denotes AP-1
T16281 46-51 http://www.uniprot.org/uniprot/P05412 denotes 1 (AP

GO-BP

Id Subject Object Predicate Lexical cue
T15854 1380-1406 http://purl.obolibrary.org/obo/GO_0032740 denotes 17 production by activated
T15853 1377-1393 http://purl.obolibrary.org/obo/GO_0032620 denotes IL-17 production
T15852 1377-1393 http://purl.obolibrary.org/obo/GO_0032660 denotes IL-17 production
T15851 1125-1136 http://purl.obolibrary.org/obo/GO_0009056 denotes degradation
T15850 871-875 http://purl.obolibrary.org/obo/GO_0016303 denotes PI3K
T15849 750-766 http://purl.obolibrary.org/obo/GO_0051092 denotes NF-κB activation
T15848 133-160 http://purl.obolibrary.org/obo/GO_1903265 denotes signaling pathway activated
T15847 133-160 http://purl.obolibrary.org/obo/GO_1902843 denotes signaling pathway activated
T15846 133-160 http://purl.obolibrary.org/obo/GO_1902046 denotes signaling pathway activated
T15845 133-160 http://purl.obolibrary.org/obo/GO_1900236 denotes signaling pathway activated
T15844 133-160 http://purl.obolibrary.org/obo/GO_0038084 denotes signaling pathway activated
T15843 133-160 http://purl.obolibrary.org/obo/GO_0009873 denotes signaling pathway activated
T15842 133-160 http://purl.obolibrary.org/obo/GO_1902204 denotes signaling pathway activated
T15841 133-160 http://purl.obolibrary.org/obo/GO_1901186 denotes signaling pathway activated
T15840 133-160 http://purl.obolibrary.org/obo/GO_0033211 denotes signaling pathway activated
T15839 133-160 http://purl.obolibrary.org/obo/GO_0009736 denotes signaling pathway activated
T15838 1356-1373 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathway
T15837 133-150 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathway
T15836 1356-1365 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T15835 133-142 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T15834 119-160 http://purl.obolibrary.org/obo/GO_1902533 denotes intracellular signaling pathway activated
T15833 1342-1373 http://purl.obolibrary.org/obo/GO_1902531 denotes intracellular signaling pathway
T15832 119-150 http://purl.obolibrary.org/obo/GO_1902531 denotes intracellular signaling pathway
T15831 1342-1373 http://purl.obolibrary.org/obo/GO_1902532 denotes intracellular signaling pathway
T15830 119-150 http://purl.obolibrary.org/obo/GO_1902532 denotes intracellular signaling pathway
T15829 1342-1373 http://purl.obolibrary.org/obo/GO_0035556 denotes intracellular signaling pathway
T15828 119-150 http://purl.obolibrary.org/obo/GO_0035556 denotes intracellular signaling pathway
T15827 1342-1373 http://purl.obolibrary.org/obo/GO_0030522 denotes intracellular signaling pathway
T15826 119-150 http://purl.obolibrary.org/obo/GO_0030522 denotes intracellular signaling pathway

GO-MF

Id Subject Object Predicate Lexical cue
T16181 1023-1034 http://purl.obolibrary.org/obo/GO_0003677 denotes DNA-binding
T16180 871-875 http://purl.obolibrary.org/obo/GO_0016303 denotes PI3K
T16179 931-944 http://purl.obolibrary.org/obo/GO_0051059 denotes NF-κB binding
T16178 504-520 http://purl.obolibrary.org/obo/GO_0051059 denotes binding of NF-κB
T16177 1027-1034 http://purl.obolibrary.org/obo/GO_0005488 denotes binding
T16176 937-944 http://purl.obolibrary.org/obo/GO_0005488 denotes binding
T16175 504-511 http://purl.obolibrary.org/obo/GO_0005488 denotes binding
T16174 213-218 http://purl.obolibrary.org/obo/GO_0016170 denotes IL-15
T16173 1377-1382 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16172 1051-1056 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16171 524-529 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16170 374-379 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16169 249-254 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17
T16168 70-75 http://purl.obolibrary.org/obo/GO_0030367 denotes IL-17

GO-CC

Id Subject Object Predicate Lexical cue
T16183 1342-1355 http://purl.obolibrary.org/obo/GO_0005622 denotes intracellular
T16182 119-132 http://purl.obolibrary.org/obo/GO_0005622 denotes intracellular

sentences

Id Subject Object Predicate Lexical cue
T15825 1195-1434 Sentence denotes In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA.
T15824 1077-1194 Sentence denotes Western blotting for IκB-α showed inhibition of degradation of IκB-α by LY294002 and PDTC at the same time (Fig. 7c).
T15823 999-1076 Sentence denotes Both agents block NF-κB DNA-binding activity in the IL-17 promoter (Fig. 7c).
T15822 843-998 Sentence denotes To confirm the link between PI3K activity and NF-κB, we performed EMSA to determine the NF-κB binding activity after treatment with both LY294002 and PDTC.
T15821 686-842 Sentence denotes In normal PBMC the same pattern was observed, but the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b).
T15820 586-685 Sentence denotes A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5).
T15819 381-585 Sentence denotes As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters in comparison with that of controls (lane 1).
T15818 92-380 Sentence denotes To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-κB recognition sites in the promoters of IL-17.
T15817 0-91 Sentence denotes Activation of the NF-κB and activator protein-1 (AP-1) pathway in the IL-17 promoter region
T147 0-91 Sentence denotes Activation of the NF-κB and activator protein-1 (AP-1) pathway in the IL-17 promoter region
T148 92-380 Sentence denotes To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-κB recognition sites in the promoters of IL-17.
T149 381-585 Sentence denotes As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters in comparison with that of controls (lane 1).
T150 586-685 Sentence denotes A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5).
T151 686-842 Sentence denotes In normal PBMC the same pattern was observed, but the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b).
T152 843-998 Sentence denotes To confirm the link between PI3K activity and NF-κB, we performed EMSA to determine the NF-κB binding activity after treatment with both LY294002 and PDTC.
T153 999-1076 Sentence denotes Both agents block NF-κB DNA-binding activity in the IL-17 promoter (Fig. 7c).
T154 1077-1194 Sentence denotes Western blotting for IκB-α showed inhibition of degradation of IκB-α by LY294002 and PDTC at the same time (Fig. 7c).
T155 1195-1434 Sentence denotes In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA.

simple1

Id Subject Object Predicate Lexical cue
T16280 1377-1382 Protein denotes IL-17
T16279 1282-1286 Protein denotes CD28
T16278 1212-1216 Protein denotes AP-1
T16277 1140-1145 Protein denotes IκB-α
T16276 1098-1103 Protein denotes IκB-α
T16275 1051-1056 Protein denotes IL-17
T16274 789-793 Protein denotes CD28
T16273 670-675 Protein denotes c-Rel
T16272 643-646 Protein denotes p50
T16271 635-638 Protein denotes p65
T16270 524-529 Protein denotes IL-17
T16269 467-471 Protein denotes CD28
T16268 374-379 Protein denotes IL-17
T16267 249-254 Protein denotes IL-17
T16266 213-218 Protein denotes IL-15
T16265 205-208 Protein denotes PHA
T16264 183-187 Protein denotes CD28
T16263 70-75 Protein denotes IL-17
T16262 49-53 Protein denotes AP-1
T16261 28-47 Protein denotes activator protein-1

DLUT931

Id Subject Object Predicate Lexical cue
T16373 1397-1406 Positive_regulation denotes activated
T16372 1383-1393 Gene_expression denotes production
T16371 1233-1242 Positive_regulation denotes activated
T16370 1111-1121 Negative_regulation denotes inhibition
T16369 1125-1136 Protein_catabolism denotes degradation
T16368 1023-1034 Binding denotes DNA-binding
T16367 494-503 Positive_regulation denotes increased
T16366 504-511 Binding denotes binding
T16365 240-248 Positive_regulation denotes inducing
T16364 255-265 Gene_expression denotes expression
T16363 0-10 Positive_regulation denotes Activation
T16362 1377-1382 Protein denotes IL-17
T16361 1282-1286 Protein denotes CD28
T16360 1212-1216 Protein denotes AP-1
T16359 1140-1145 Protein denotes IκB-α
T16358 1098-1103 Protein denotes IκB-α
T16357 1051-1056 Protein denotes IL-17
T16356 789-793 Protein denotes CD28
T16355 670-675 Protein denotes c-Rel
T16354 643-646 Protein denotes p50
T16353 635-638 Protein denotes p65
T16352 467-471 Protein denotes CD28
T16351 524-529 Protein denotes IL-17
T16350 374-379 Protein denotes IL-17
T16349 249-254 Protein denotes IL-17
T16348 213-218 Protein denotes IL-15
T16347 205-208 Protein denotes PHA
T16346 183-187 Protein denotes CD28
T16345 70-75 Protein denotes IL-17
T16344 49-53 Protein denotes AP-1
T16343 28-47 Protein denotes activator protein-1
R8871 T16343 T16363 themeOf activator protein-1,Activation
R8872 T16349 T16364 themeOf IL-17,expression
R8873 T16351 T16366 themeOf IL-17,binding
R8874 T16357 T16368 themeOf IL-17,DNA-binding
R8875 T16359 T16369 themeOf IκB-α,degradation
R8876 T16360 T16371 themeOf AP-1,activated
R8877 T16362 T16372 themeOf IL-17,production
R8878 T16364 T16365 themeOf expression,inducing
R8879 T16366 T16367 themeOf binding,increased
R8880 T16369 T16370 themeOf degradation,inhibition
R8881 T16372 T16373 themeOf production,activated

bionlp-st-ge-2016-test-ihmc

Id Subject Object Predicate Lexical cue
T16780 750-793 Positive_regulation denotes NF-κB activation by anti-CD3 plus anti-CD28
T16779 750-793 Positive_regulation denotes NF-κB activation by anti-CD3 plus anti-CD28
T16778 1377-1433 Gene_expression denotes IL-17 production by activated PBMC from patients with RA
T16777 1122-1145 Protein_catabolism denotes of degradation of IκB-α
T16776 0-54 Positive_regulation denotes Activation of the NF-κB and activator protein-1 (AP-1)
T16775 0-54 Positive_regulation denotes Activation of the NF-κB and activator protein-1 (AP-1)
T16774 1104-1157 Negative_regulation denotes showed inhibition of degradation of IκB-α by LY294002
T16773 249-266 Gene_expression denotes IL-17 expression,
T16772 494-539 Positive_regulation denotes increased binding of NF-κB to IL-17 promoters
T16771 402-539 Binding denotes nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
T16770 524-529 Protein denotes IL-17
T16769 1051-1056 Protein denotes IL-17
T16768 330-335 Protein denotes NF-κB
T16767 1047-1075 Entity denotes the IL-17 promoter (Fig. 7c)
T16766 213-218 Protein denotes IL-15
T16765 330-353 Entity denotes NF-κB recognition sites
T16764 249-254 Protein denotes IL-17
T16736 1319-1329 Protein denotes that NF-κB
T16735 424-426 Protein denotes RA
T16734 670-684 Protein denotes c-Rel (lane 5)
T16733 189-203 Protein denotes concanavalin A
T16732 115-132 Entity denotes the intracellular
T16731 1208-1224 Protein denotes the AP-1 pathway
T16730 643-646 Protein denotes p50
T16729 512-520 Protein denotes of NF-κB
T16728 178-219 Protein denotes anti-CD28, concanavalin A, PHA and IL-15,
T16727 521-539 Entity denotes to IL-17 promoters
T16726 393-396 Protein denotes Fig
T16725 1098-1103 Protein denotes IκB-α
T16724 770-778 Protein denotes anti-CD3
T16723 689-700 Entity denotes normal PBMC
T16722 1263-1271 Protein denotes anti-CD3
T16721 462-480 Protein denotes anti-CD28 (lane 2)
T16720 205-208 Protein denotes PHA
T16719 1017-1022 Protein denotes NF-κB
T16718 980-988 Entity denotes LY294002
T16763 1342-1355 Entity denotes intracellular
T16762 164-172 Protein denotes anti-CD3
T16761 750-755 Protein denotes NF-κB
T16760 66-91 Entity denotes the IL-17 promoter region
T16759 49-53 Protein denotes AP-1
T16758 14-23 Protein denotes the NF-κB
T16757 374-379 Protein denotes IL-17
T16756 1394-1411 Entity denotes by activated PBMC
T16755 28-47 Protein denotes activator protein-1
T16754 635-638 Protein denotes p65
T16753 1185-1188 Protein denotes Fig
T16752 424-480 Entity denotes RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2)
T16751 357-379 Entity denotes the promoters of IL-17
T16750 1277-1286 Protein denotes anti-CD28
T16749 824-826 Protein denotes RA
T16748 448-456 Protein denotes anti-CD3
T16747 1431-1433 Protein denotes RA
T16746 402-480 Entity denotes nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2)
T16745 70-75 Protein denotes IL-17
T16744 1377-1382 Protein denotes IL-17
T16743 824-831 Entity denotes RA PBMC
T16742 1137-1145 Protein denotes of IκB-α
T16741 889-894 Protein denotes NF-κB
T16740 833-836 Protein denotes Fig
T16739 784-793 Protein denotes anti-CD28
T16738 871-875 Protein denotes PI3K
T16737 1146-1157 Entity denotes by LY294002
R9175 T16724 T16779 causeOf anti-CD3,NF-κB activation by anti-CD3 plus anti-CD28
R9176 T16727 T16770 partOf to IL-17 promoters,IL-17
R9177 T16727 T16771 themeOf to IL-17 promoters,nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
R9178 T16729 T16771 themeOf of NF-κB,nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
R9179 T16737 T16774 causeOf by LY294002,showed inhibition of degradation of IκB-α by LY294002
R9180 T16739 T16780 causeOf anti-CD28,NF-κB activation by anti-CD3 plus anti-CD28
R9181 T16742 T16777 themeOf of IκB-α,of degradation of IκB-α
R9182 T16744 T16778 themeOf IL-17,IL-17 production by activated PBMC from patients with RA
R9183 T16755 T16776 themeOf activator protein-1,Activation of the NF-κB and activator protein-1 (AP-1)
R9184 T16758 T16775 themeOf the NF-κB,Activation of the NF-κB and activator protein-1 (AP-1)
R9185 T16761 T16779 themeOf NF-κB,NF-κB activation by anti-CD3 plus anti-CD28
R9186 T16761 T16780 themeOf NF-κB,NF-κB activation by anti-CD3 plus anti-CD28
R9187 T16764 T16773 themeOf IL-17,"IL-17 expression,"
R9188 T16767 T16769 partOf the IL-17 promoter (Fig. 7c),IL-17
R9189 T16771 T16772 themeOf nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters,increased binding of NF-κB to IL-17 promoters
R9190 T16777 T16774 themeOf of degradation of IκB-α,showed inhibition of degradation of IκB-α by LY294002

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T16660 1433-1434 . denotes .
T16659 1431-1433 NNP denotes RA
T16658 1426-1430 IN denotes with
T16657 1417-1425 NNS denotes patients
T16656 1412-1416 IN denotes from
T16655 1407-1411 NNP denotes PBMC
T16654 1397-1406 VBN denotes activated
T16653 1394-1396 IN denotes by
T16652 1383-1393 NN denotes production
T16651 1377-1382 JJ denotes IL-17
T16650 1374-1376 IN denotes in
T16649 1366-1373 NN denotes pathway
T16648 1356-1365 VBG denotes signaling
T16647 1342-1355 JJ denotes intracellular
T16646 1337-1341 JJ denotes main
T16645 1333-1336 DT denotes the
T16644 1330-1332 VBZ denotes is
T16643 1324-1329 NNP denotes NF-κB
T16620 1195-1197 IN denotes In
T16619 1193-1194 . denotes .
T16618 1192-1193 -RRB- denotes )
T16617 1190-1192 CD denotes 7c
T16616 1185-1189 NNP denotes Fig.
T16615 1184-1185 -LRB- denotes (
T16614 1179-1183 NN denotes time
T16613 1174-1178 JJ denotes same
T16612 1170-1173 DT denotes the
T16611 1167-1169 IN denotes at
T16610 1162-1166 NNP denotes PDTC
T16609 1158-1161 CC denotes and
T16608 1149-1157 NNP denotes LY294002
T16607 1146-1148 IN denotes by
T16606 1140-1145 JJ denotes IκB-α
T16605 1137-1139 IN denotes of
T16604 1125-1136 NN denotes degradation
T16603 1122-1124 IN denotes of
T16602 1111-1121 NN denotes inhibition
T16601 1104-1110 VBD denotes showed
T16600 1098-1103 JJ denotes IκB-α
T16599 1094-1097 IN denotes for
T16598 1085-1093 VBG denotes blotting
T16597 1077-1084 JJ denotes Western
T16596 1075-1076 . denotes .
T16595 1074-1075 -RRB- denotes )
T16594 1072-1074 CD denotes 7c
T16593 1067-1071 NNP denotes Fig.
T16592 1066-1067 -LRB- denotes (
T16591 1057-1065 NN denotes promoter
T16590 1051-1056 NNP denotes IL-17
T16589 1047-1050 DT denotes the
T16588 1044-1046 IN denotes in
T16587 1035-1043 NN denotes activity
T16586 1023-1034 JJ denotes DNA-binding
T16585 1017-1022 NNP denotes NF-κB
T16584 1011-1016 NN denotes block
T16583 1004-1010 NNS denotes agents
T16582 999-1003 DT denotes Both
T16581 997-998 . denotes .
T16580 993-997 NNP denotes PDTC
T16579 989-992 CC denotes and
T16578 980-988 CD denotes LY294002
T16577 975-979 DT denotes both
T16576 970-974 IN denotes with
T16575 960-969 NN denotes treatment
T16574 954-959 IN denotes after
T16573 945-953 NN denotes activity
T16572 937-944 JJ denotes binding
T16571 931-936 JJ denotes NF-κB
T16570 927-930 DT denotes the
T16569 917-926 VB denotes determine
T16568 914-916 TO denotes to
T16567 909-913 NNP denotes EMSA
T16566 899-908 VBD denotes performed
T16565 896-898 PRP denotes we
T16564 894-895 , denotes ,
T16563 889-894 NN denotes NF-κB
T16562 885-888 CC denotes and
T16561 876-884 NN denotes activity
T16560 871-875 JJ denotes PI3K
T16559 863-870 IN denotes between
T16558 858-862 NN denotes link
T16557 854-857 DT denotes the
T16556 846-853 VB denotes confirm
T16555 843-845 TO denotes To
T16554 841-842 . denotes .
T16553 840-841 -RRB- denotes )
T16552 838-840 CD denotes 7b
T16551 833-837 NNP denotes Fig.
T16550 832-833 -LRB- denotes (
T16549 827-831 NNP denotes PBMC
T16548 824-826 NNP denotes RA
T16547 821-823 IN denotes in
T16546 816-820 DT denotes that
T16545 811-815 IN denotes than
T16544 803-810 JJ denotes intense
T16543 798-802 JJR denotes less
T16542 794-797 VBD denotes was
T16541 784-793 JJ denotes anti-CD28
T16540 779-783 CC denotes plus
T16539 770-778 JJ denotes anti-CD3
T16538 767-769 IN denotes by
T16537 756-766 NN denotes activation
T16536 750-755 JJ denotes NF-κB
T16535 747-749 IN denotes of
T16534 740-746 NN denotes degree
T16533 736-739 DT denotes the
T16532 732-735 CC denotes but
T16531 730-731 , denotes ,
T16530 722-730 VBN denotes observed
T16529 718-721 VBD denotes was
T16528 710-717 NN denotes pattern
T16527 705-709 JJ denotes same
T16526 701-704 DT denotes the
T16525 696-700 NNP denotes PBMC
T16524 689-695 JJ denotes normal
T16523 686-688 IN denotes In
T16522 684-685 . denotes .
T16521 683-684 -RRB- denotes )
T16520 682-683 CD denotes 5
T16519 677-681 NN denotes lane
T16518 676-677 -LRB- denotes (
T16517 670-675 NNP denotes c-Rel
T16516 667-669 IN denotes in
T16515 663-666 RB denotes not
T16514 661-662 -RRB- denotes )
T16513 660-661 CD denotes 4
T16512 656-659 CC denotes and
T16511 654-655 CD denotes 3
T16510 648-653 NNS denotes lanes
T16509 647-648 -LRB- denotes (
T16508 643-646 CD denotes p50
T16507 639-642 CC denotes and
T16506 635-638 CD denotes p65
T16505 632-634 IN denotes in
T16504 626-631 NNS denotes bands
T16503 618-625 VBN denotes shifted
T16502 605-617 VBD denotes demonstrated
T16501 599-604 NN denotes assay
T16500 588-598 NN denotes supershift
T16499 586-587 DT denotes A
T16498 584-585 . denotes .
T16497 583-584 -RRB- denotes )
T16496 582-583 CD denotes 1
T16495 577-581 NN denotes lane
T16494 576-577 -LRB- denotes (
T16493 567-575 NNS denotes controls
T16492 564-566 IN denotes of
T16491 559-563 DT denotes that
T16490 554-558 IN denotes with
T16489 543-553 NN denotes comparison
T16488 540-542 IN denotes in
T16487 530-539 NNS denotes promoters
T16486 524-529 NNP denotes IL-17
T16485 521-523 TO denotes to
T16484 515-520 NN denotes NF-κB
T16483 512-514 IN denotes of
T16482 504-511 JJ denotes binding
T16481 494-503 VBN denotes increased
T16480 481-493 VBD denotes demonstrated
T16479 479-480 -RRB- denotes )
T16478 478-479 CD denotes 2
T16477 473-477 NN denotes lane
T16476 472-473 -LRB- denotes (
T16475 462-471 JJ denotes anti-CD28
T16474 457-461 CC denotes plus
T16473 448-456 JJ denotes anti-CD3
T16472 443-447 IN denotes with
T16471 432-442 VBD denotes stimulated
T16470 427-431 NNP denotes PBMC
T16469 424-426 NNP denotes RA
T16468 419-423 IN denotes from
T16467 410-418 NNS denotes extracts
T16466 402-409 JJ denotes nuclear
T16465 400-401 , denotes ,
T16464 398-400 CD denotes 7a
T16463 393-397 NNP denotes Fig.
T16462 390-392 IN denotes in
T16461 384-389 VBN denotes shown
T16460 381-383 IN denotes As
T16459 379-380 . denotes .
T16458 374-379 NNP denotes IL-17
T16457 371-373 IN denotes of
T16456 361-370 NNS denotes promoters
T16455 357-360 DT denotes the
T16454 354-356 IN denotes in
T16453 348-353 NNS denotes sites
T16452 336-347 NN denotes recognition
T16451 330-335 NN denotes NF-κB
T16450 327-329 IN denotes of
T16449 325-326 -RRB- denotes )
T16448 321-325 NNP denotes EMSA
T16447 320-321 -LRB- denotes (
T16446 314-319 NN denotes assay
T16445 299-313 NN denotes mobility-shift
T16444 283-298 JJ denotes electrophoretic
T16443 280-282 DT denotes an
T16442 270-279 VBD denotes performed
T16441 267-269 PRP denotes we
T16440 265-266 , denotes ,
T16439 255-265 NN denotes expression
T16438 249-254 NNP denotes IL-17
T16437 240-248 VBG denotes inducing
T16436 236-239 IN denotes for
T16435 224-235 JJ denotes responsible
T16434 220-223 CC denotes and
T16433 218-219 , denotes ,
T16432 213-218 NNP denotes IL-15
T16431 209-212 CC denotes and
T16430 205-208 NNP denotes PHA
T16429 203-204 , denotes ,
T16428 202-203 DT denotes A
T16427 189-201 JJ denotes concanavalin
T16426 187-188 , denotes ,
T16425 178-187 JJ denotes anti-CD28
T16424 173-177 CC denotes plus
T16423 164-172 JJ denotes anti-CD3
T16422 161-163 IN denotes by
T16421 151-160 VBN denotes activated
T16420 143-150 NN denotes pathway
T16419 133-142 VBG denotes signaling
T16418 119-132 JJ denotes intracellular
T16417 115-118 DT denotes the
T16416 107-114 RB denotes further
T16415 95-106 VB denotes investigate
T16414 92-94 TO denotes To
T16413 85-91 NN denotes region
T16412 76-84 NN denotes promoter
T16411 70-75 NNP denotes IL-17
T16410 66-69 DT denotes the
T16409 63-65 IN denotes in
T16408 55-62 NN denotes pathway
T16407 53-54 -RRB- denotes )
T16406 49-53 NN denotes AP-1
T16405 48-49 -LRB- denotes (
T16402 24-27 CC denotes and
T16401 18-23 NN denotes NF-κB
T16400 14-17 DT denotes the
T16399 11-13 IN denotes of
T16398 0-10 NNP denotes Activation
T16642 1319-1323 IN denotes that
T16641 1305-1318 VBG denotes demonstrating
T16640 1303-1304 , denotes ,
T16639 1302-1303 -RRB- denotes )
T16638 1297-1302 VBN denotes shown
T16637 1293-1296 RB denotes not
T16636 1288-1292 NNS denotes data
T16635 1287-1288 -LRB- denotes (
T16634 1277-1286 JJ denotes anti-CD28
T16633 1272-1276 CC denotes plus
T16632 1263-1271 JJ denotes anti-CD3
T16631 1258-1262 IN denotes with
T16630 1246-1257 NN denotes stimulation
T16629 1243-1245 IN denotes by
T16628 1233-1242 VBN denotes activated
T16627 1229-1232 RB denotes not
T16626 1225-1228 VBD denotes was
T16625 1217-1224 NN denotes pathway
T16624 1212-1216 NNP denotes AP-1
T16623 1208-1211 DT denotes the
T16622 1206-1207 , denotes ,
T16621 1198-1206 NN denotes contrast
T16404 38-47 NN denotes protein-1
T16403 28-37 NN denotes activator
R8888 T16398 T16415 nsubj Activation,investigate
R8889 T16399 T16398 prep of,Activation
R8890 T16400 T16401 det the,NF-κB
R8891 T16401 T16399 pobj NF-κB,of
R8892 T16402 T16401 cc and,NF-κB
R8893 T16403 T16404 amod activator,protein-1
R8894 T16404 T16401 conj protein-1,NF-κB
R8895 T16405 T16406 punct (,AP-1
R8896 T16406 T16404 appos AP-1,protein-1
R8897 T16407 T16406 punct ),AP-1
R8898 T16408 T16398 conj pathway,Activation
R8899 T16409 T16398 prep in,Activation
R8900 T16410 T16413 det the,region
R8901 T16411 T16413 compound IL-17,region
R8902 T16412 T16413 compound promoter,region
R8903 T16413 T16409 pobj region,in
R8904 T16414 T16415 aux To,investigate
R8905 T16415 T16442 advcl investigate,performed
R8906 T16416 T16415 advmod further,investigate
R8907 T16417 T16420 det the,pathway
R8908 T16418 T16420 amod intracellular,pathway
R8909 T16419 T16420 amod signaling,pathway
R8910 T16420 T16415 dobj pathway,investigate
R8911 T16421 T16420 acl activated,pathway
R8912 T16422 T16421 agent by,activated
R8913 T16423 T16430 amod anti-CD3,PHA
R8914 T16424 T16423 cc plus,anti-CD3
R8915 T16425 T16423 conj anti-CD28,anti-CD3
R8916 T16426 T16425 punct ",",anti-CD28
R8917 T16427 T16428 compound concanavalin,A
R8918 T16428 T16425 conj A,anti-CD28
R8919 T16429 T16428 punct ",",A
R8920 T16430 T16422 pobj PHA,by
R8921 T16431 T16430 cc and,PHA
R8922 T16432 T16430 conj IL-15,PHA
R8923 T16433 T16432 punct ",",IL-15
R8924 T16434 T16421 cc and,activated
R8925 T16435 T16421 conj responsible,activated
R8926 T16436 T16435 prep for,responsible
R8927 T16437 T16436 pcomp inducing,for
R8928 T16438 T16439 compound IL-17,expression
R8929 T16439 T16437 dobj expression,inducing
R8930 T16440 T16442 punct ",",performed
R8931 T16441 T16442 nsubj we,performed
R8932 T16442 T16442 ROOT performed,performed
R8933 T16443 T16446 det an,assay
R8934 T16444 T16446 amod electrophoretic,assay
R8935 T16445 T16446 compound mobility-shift,assay
R8936 T16446 T16442 dobj assay,performed
R8937 T16447 T16446 punct (,assay
R8938 T16448 T16446 appos EMSA,assay
R8939 T16449 T16446 punct ),assay
R8940 T16450 T16446 prep of,assay
R8941 T16451 T16453 compound NF-κB,sites
R8942 T16452 T16453 compound recognition,sites
R8943 T16453 T16450 pobj sites,of
R8944 T16454 T16453 prep in,sites
R8945 T16455 T16456 det the,promoters
R8946 T16456 T16454 pobj promoters,in
R8947 T16457 T16456 prep of,promoters
R8948 T16458 T16457 pobj IL-17,of
R8949 T16459 T16442 punct .,performed
R8950 T16460 T16461 mark As,shown
R8951 T16461 T16471 advcl shown,stimulated
R8952 T16462 T16461 prep in,shown
R8953 T16463 T16462 pobj Fig.,in
R8954 T16464 T16463 nummod 7a,Fig.
R8955 T16465 T16463 punct ",",Fig.
R8956 T16466 T16467 amod nuclear,extracts
R8957 T16467 T16471 nsubj extracts,stimulated
R8958 T16468 T16467 prep from,extracts
R8959 T16469 T16470 compound RA,PBMC
R8960 T16470 T16468 pobj PBMC,from
R8961 T16471 T16471 ROOT stimulated,stimulated
R8962 T16472 T16471 prep with,stimulated
R8963 T16473 T16472 pobj anti-CD3,with
R8964 T16474 T16473 cc plus,anti-CD3
R8965 T16475 T16473 conj anti-CD28,anti-CD3
R8966 T16476 T16477 punct (,lane
R8967 T16477 T16473 appos lane,anti-CD3
R8968 T16478 T16477 nummod 2,lane
R8969 T16479 T16471 punct ),stimulated
R8970 T16480 T16471 conj demonstrated,stimulated
R8971 T16481 T16482 amod increased,binding
R8972 T16482 T16480 dobj binding,demonstrated
R8973 T16483 T16482 prep of,binding
R8974 T16484 T16483 pobj NF-κB,of
R8975 T16485 T16484 prep to,NF-κB
R8976 T16486 T16487 compound IL-17,promoters
R8977 T16487 T16485 pobj promoters,to
R8978 T16488 T16480 prep in,demonstrated
R8979 T16489 T16488 pobj comparison,in
R8980 T16490 T16489 prep with,comparison
R8981 T16491 T16490 pobj that,with
R8982 T16492 T16491 prep of,that
R8983 T16493 T16492 pobj controls,of
R8984 T16494 T16495 punct (,lane
R8985 T16495 T16493 parataxis lane,controls
R8986 T16496 T16495 nummod 1,lane
R8987 T16497 T16495 punct ),lane
R8988 T16498 T16471 punct .,stimulated
R8989 T16499 T16501 det A,assay
R8990 T16500 T16501 compound supershift,assay
R8991 T16501 T16502 nsubj assay,demonstrated
R8992 T16502 T16502 ROOT demonstrated,demonstrated
R8993 T16503 T16504 amod shifted,bands
R8994 T16504 T16502 dobj bands,demonstrated
R8995 T16505 T16502 prep in,demonstrated
R8996 T16506 T16510 nummod p65,lanes
R8997 T16507 T16506 cc and,p65
R8998 T16508 T16506 conj p50,p65
R8999 T16509 T16510 punct (,lanes
R9000 T16510 T16505 pobj lanes,in
R9001 T16511 T16510 nummod 3,lanes
R9002 T16512 T16511 cc and,3
R9003 T16513 T16511 conj 4,3
R9004 T16514 T16511 punct ),3
R9005 T16515 T16510 neg not,lanes
R9006 T16516 T16510 prep in,lanes
R9007 T16517 T16516 pobj c-Rel,in
R9008 T16518 T16519 punct (,lane
R9009 T16519 T16517 appos lane,c-Rel
R9010 T16520 T16519 nummod 5,lane
R9011 T16521 T16519 punct ),lane
R9012 T16522 T16502 punct .,demonstrated
R9013 T16523 T16530 prep In,observed
R9014 T16524 T16523 pobj normal,In
R9015 T16525 T16530 nsubjpass PBMC,observed
R9016 T16526 T16528 det the,pattern
R9017 T16527 T16528 amod same,pattern
R9018 T16528 T16525 appos pattern,PBMC
R9019 T16529 T16530 auxpass was,observed
R9020 T16530 T16530 ROOT observed,observed
R9021 T16531 T16530 punct ",",observed
R9022 T16532 T16530 cc but,observed
R9023 T16533 T16534 det the,degree
R9024 T16534 T16542 nsubj degree,was
R9025 T16535 T16534 prep of,degree
R9026 T16536 T16537 amod NF-κB,activation
R9027 T16537 T16535 pobj activation,of
R9028 T16538 T16537 prep by,activation
R9029 T16539 T16542 nsubj anti-CD3,was
R9030 T16540 T16539 cc plus,anti-CD3
R9031 T16541 T16539 conj anti-CD28,anti-CD3
R9032 T16542 T16530 conj was,observed
R9033 T16543 T16544 advmod less,intense
R9034 T16544 T16542 acomp intense,was
R9035 T16545 T16544 prep than,intense
R9036 T16546 T16545 pobj that,than
R9037 T16547 T16546 prep in,that
R9038 T16548 T16549 compound RA,PBMC
R9039 T16549 T16547 pobj PBMC,in
R9040 T16550 T16549 punct (,PBMC
R9041 T16551 T16549 appos Fig.,PBMC
R9042 T16552 T16551 nummod 7b,Fig.
R9043 T16553 T16549 punct ),PBMC
R9044 T16554 T16542 punct .,was
R9045 T16555 T16556 aux To,confirm
R9046 T16556 T16566 advcl confirm,performed
R9047 T16557 T16558 det the,link
R9048 T16558 T16556 dobj link,confirm
R9049 T16559 T16558 prep between,link
R9050 T16560 T16561 amod PI3K,activity
R9051 T16561 T16559 pobj activity,between
R9052 T16562 T16561 cc and,activity
R9053 T16563 T16561 conj NF-κB,activity
R9054 T16564 T16566 punct ",",performed
R9055 T16565 T16566 nsubj we,performed
R9056 T16566 T16566 ROOT performed,performed
R9057 T16567 T16566 dobj EMSA,performed
R9058 T16568 T16569 aux to,determine
R9059 T16569 T16566 advcl determine,performed
R9060 T16570 T16573 det the,activity
R9061 T16571 T16573 amod NF-κB,activity
R9062 T16572 T16573 amod binding,activity
R9063 T16573 T16569 dobj activity,determine
R9064 T16574 T16569 prep after,determine
R9065 T16575 T16574 pobj treatment,after
R9066 T16576 T16575 prep with,treatment
R9067 T16577 T16578 det both,LY294002
R9068 T16578 T16576 pobj LY294002,with
R9069 T16579 T16578 cc and,LY294002
R9070 T16580 T16578 conj PDTC,LY294002
R9071 T16581 T16566 punct .,performed
R9072 T16582 T16583 preconj Both,agents
R9073 T16583 T16584 nsubj agents,block
R9074 T16584 T16584 ROOT block,block
R9075 T16585 T16587 nmod NF-κB,activity
R9076 T16586 T16587 amod DNA-binding,activity
R9077 T16587 T16584 dobj activity,block
R9078 T16588 T16587 prep in,activity
R9079 T16589 T16591 det the,promoter
R9080 T16590 T16591 compound IL-17,promoter
R9081 T16591 T16588 pobj promoter,in
R9082 T16592 T16584 punct (,block
R9083 T16593 T16584 npadvmod Fig.,block
R9084 T16594 T16593 nummod 7c,Fig.
R9085 T16595 T16584 punct ),block
R9086 T16596 T16584 punct .,block
R9087 T16597 T16598 amod Western,blotting
R9088 T16598 T16601 nsubj blotting,showed
R9089 T16599 T16598 prep for,blotting
R9090 T16600 T16601 nsubj IκB-α,showed
R9091 T16601 T16601 ROOT showed,showed
R9092 T16602 T16601 dobj inhibition,showed
R9093 T16603 T16602 prep of,inhibition
R9094 T16604 T16603 pobj degradation,of
R9095 T16605 T16604 prep of,degradation
R9096 T16606 T16605 pobj IκB-α,of
R9097 T16607 T16601 prep by,showed
R9098 T16608 T16607 pobj LY294002,by
R9099 T16609 T16608 cc and,LY294002
R9100 T16610 T16608 conj PDTC,LY294002
R9101 T16611 T16601 prep at,showed
R9102 T16612 T16614 det the,time
R9103 T16613 T16614 amod same,time
R9104 T16614 T16611 pobj time,at
R9105 T16615 T16601 punct (,showed
R9106 T16616 T16601 dobj Fig.,showed
R9107 T16617 T16616 nummod 7c,Fig.
R9108 T16618 T16616 punct ),Fig.
R9109 T16619 T16601 punct .,showed
R9110 T16620 T16628 prep In,activated
R9111 T16621 T16620 pobj contrast,In
R9112 T16622 T16628 punct ",",activated
R9113 T16623 T16625 det the,pathway
R9114 T16624 T16625 compound AP-1,pathway
R9115 T16625 T16628 nsubjpass pathway,activated
R9116 T16626 T16628 auxpass was,activated
R9117 T16627 T16628 neg not,activated
R9118 T16628 T16628 ROOT activated,activated
R9119 T16629 T16628 agent by,activated
R9120 T16630 T16629 pobj stimulation,by
R9121 T16631 T16628 prep with,activated
R9122 T16632 T16636 amod anti-CD3,data
R9123 T16633 T16632 cc plus,anti-CD3
R9124 T16634 T16632 conj anti-CD28,anti-CD3
R9125 T16635 T16636 punct (,data
R9126 T16636 T16631 pobj data,with
R9127 T16637 T16638 neg not,shown
R9128 T16638 T16636 acl shown,data
R9129 T16639 T16636 punct ),data
R9130 T16640 T16628 punct ",",activated
R9131 T16641 T16628 advcl demonstrating,activated
R9132 T16642 T16644 mark that,is
R9133 T16643 T16644 nsubj NF-κB,is
R9134 T16644 T16641 ccomp is,demonstrating
R9135 T16645 T16649 det the,pathway
R9136 T16646 T16649 amod main,pathway
R9137 T16647 T16649 amod intracellular,pathway
R9138 T16648 T16649 amod signaling,pathway
R9139 T16649 T16644 attr pathway,is
R9140 T16650 T16649 prep in,pathway
R9141 T16651 T16652 amod IL-17,production
R9142 T16652 T16650 pobj production,in
R9143 T16653 T16649 prep by,pathway
R9144 T16654 T16655 amod activated,PBMC
R9145 T16655 T16653 pobj PBMC,by
R9146 T16656 T16649 prep from,pathway
R9147 T16657 T16656 pobj patients,from
R9148 T16658 T16649 prep with,pathway
R9149 T16659 T16658 pobj RA,with
R9150 T16660 T16628 punct .,activated

bionlp-st-ge-2016-test-tees

Id Subject Object Predicate Lexical cue
T16257 1324-1329 Protein denotes NF-κB
T16256 1277-1286 Protein denotes anti-CD28
T16255 1263-1271 Protein denotes anti-CD3
T16254 1212-1216 Protein denotes AP-1
T16253 1111-1121 Negative_regulation denotes inhibition
T16252 1125-1136 Protein_catabolism denotes degradation
T16251 1185-1192 Protein denotes Fig. 7c
T16250 1140-1145 Protein denotes IκB-α
T16249 1098-1103 Protein denotes IκB-α
T16248 1011-1016 Negative_regulation denotes block
T16247 1011-1016 Negative_regulation denotes block
T16246 1067-1074 Protein denotes Fig. 7c
T16245 1051-1065 Protein denotes IL-17 promoter
T16241 889-894 Protein denotes NF-κB
T16240 871-875 Protein denotes PI3K
T16239 803-810 Binding denotes intense
T16238 756-766 Positive_regulation denotes activation
T16237 756-766 Positive_regulation denotes activation
T16236 833-840 Protein denotes Fig. 7b
T16235 824-831 Protein denotes RA PBMC
T16234 784-793 Protein denotes anti-CD28
T16233 770-778 Protein denotes anti-CD3
T16232 750-755 Protein denotes NF-κB
T16231 643-646 Protein denotes p50
T16230 635-638 Protein denotes p65
T16229 494-503 Positive_regulation denotes increased
T16228 494-503 Positive_regulation denotes increased
T16227 504-511 Binding denotes binding
T16226 504-511 Binding denotes binding
T16225 432-442 Positive_regulation denotes stimulated
T16224 432-442 Positive_regulation denotes stimulated
T16223 524-539 Protein denotes IL-17 promoters
T16222 515-520 Protein denotes NF-κB
T16221 462-471 Protein denotes anti-CD28
T16220 448-456 Protein denotes anti-CD3
T16219 424-431 Protein denotes RA PBMC
T16218 393-396 Protein denotes Fig
T16217 240-248 Positive_regulation denotes inducing
T16216 255-265 Gene_expression denotes expression
T16215 374-379 Protein denotes IL-17
T16214 330-353 Protein denotes NF-κB recognition sites
T16213 249-254 Protein denotes IL-17
T16212 213-218 Protein denotes IL-15
T16211 205-208 Protein denotes PHA
T16210 189-203 Protein denotes concanavalin A
T16209 178-187 Protein denotes anti-CD28
T16208 164-172 Protein denotes anti-CD3
T16207 0-10 Positive_regulation denotes Activation
T16206 0-10 Positive_regulation denotes Activation
T16205 0-10 Positive_regulation denotes Activation
T16204 70-84 Protein denotes IL-17 promoter
T16203 49-53 Protein denotes AP-1
T16202 28-47 Protein denotes activator protein-1
T16201 18-23 Protein denotes NF-κB
T16244 1017-1022 Protein denotes NF-κB
T16243 937-944 Binding denotes binding
T16242 931-936 Protein denotes NF-κB
R8837 T16201 T16205 themeOf NF-κB,Activation
R8838 T16202 T16206 themeOf activator protein-1,Activation
R8839 T16203 T16207 themeOf AP-1,Activation
R8840 T16213 T16216 themeOf IL-17,expression
R8841 T16216 T16217 themeOf expression,inducing
R8842 T16219 T16224 themeOf RA PBMC,stimulated
R8843 T16220 T16225 themeOf anti-CD3,stimulated
R8844 T16221 T16224 causeOf anti-CD28,stimulated
R8845 T16221 T16225 causeOf anti-CD28,stimulated
R8846 T16222 T16226 themeOf NF-κB,binding
R8847 T16222 T16227 themeOf NF-κB,binding
R8848 T16223 T16227 themeOf IL-17 promoters,binding
R8849 T16226 T16228 themeOf binding,increased
R8850 T16227 T16229 themeOf binding,increased
R8851 T16232 T16237 themeOf NF-κB,activation
R8852 T16232 T16238 themeOf NF-κB,activation
R8853 T16233 T16237 causeOf anti-CD3,activation
R8854 T16234 T16238 causeOf anti-CD28,activation
R8855 T16235 T16239 themeOf RA PBMC,intense
R8856 T16242 T16243 themeOf NF-κB,binding
R8857 T16245 T16247 themeOf IL-17 promoter,block
R8858 T16246 T16248 themeOf Fig. 7c,block
R8859 T16250 T16252 themeOf IκB-α,degradation
R8860 T16252 T16253 themeOf degradation,inhibition

testone

Id Subject Object Predicate Lexical cue
T15531 1397-1406 Positive_regulation denotes activated
T15530 1383-1393 Gene_expression denotes production
T15529 1125-1136 Protein_catabolism denotes degradation
T15528 1111-1121 Negative_regulation denotes inhibition
T15527 1027-1034 Binding denotes binding
T15526 1011-1016 Negative_regulation denotes block
T15525 937-944 Binding denotes binding
T15524 504-511 Binding denotes binding
T15523 494-503 Positive_regulation denotes increased
T15522 255-265 Gene_expression denotes expression
T15521 240-248 Positive_regulation denotes inducing
T15520 224-235 Regulation denotes responsible
T15519 1377-1382 Protein denotes IL-17
T15518 1282-1286 Protein denotes CD28
T15517 1212-1216 Protein denotes AP-1
T15516 1140-1145 Protein denotes IκB-α
T15515 1098-1103 Protein denotes IκB-α
T15514 1051-1056 Protein denotes IL-17
T15513 789-793 Protein denotes CD28
T15512 670-675 Protein denotes c-Rel
T15511 643-646 Protein denotes p50
T15510 635-638 Protein denotes p65
T15509 524-529 Protein denotes IL-17
T15508 467-471 Protein denotes CD28
T15507 374-379 Protein denotes IL-17
T15506 249-254 Protein denotes IL-17
T15505 213-218 Protein denotes IL-15
T15504 205-208 Protein denotes PHA
T15503 183-187 Protein denotes CD28
T15502 70-75 Protein denotes IL-17
T15501 49-53 Protein denotes AP-1
T15500 28-47 Protein denotes activator protein-1
R8542 T15501 T15500 equivalentTo AP-1,activator protein-1
R8543 T15504 T15521 causeOf PHA,inducing
R8544 T15505 T15521 causeOf IL-15,inducing
R8545 T15506 T15522 themeOf IL-17,expression
R8546 T15509 T15524 themeOf IL-17,binding
R8547 T15516 T15529 themeOf IκB-α,degradation
R8548 T15519 T15530 themeOf IL-17,production
R8549 T15521 T15520 themeOf inducing,responsible
R8550 T15522 T15521 themeOf expression,inducing
R8551 T15524 T15523 themeOf binding,increased
R8552 T15527 T15526 themeOf binding,block
R8553 T15529 T15528 themeOf degradation,inhibition